Zoetis Inc. (NYSE:ZTS) Shares Sold by Taikang Asset Management Hong Kong Co Ltd

Taikang Asset Management Hong Kong Co Ltd lessened its stake in shares of Zoetis Inc. (NYSE:ZTS) by 50.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,940 shares of the company’s stock after selling 25,940 shares during the quarter. Taikang Asset Management Hong Kong Co Ltd’s holdings in Zoetis were worth $4,226,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Atlantic Edge Private Wealth Management LLC increased its holdings in Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 140 shares during the last quarter. Rakuten Securities Inc. boosted its position in shares of Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after buying an additional 166 shares during the period. Dunhill Financial LLC boosted its position in shares of Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after buying an additional 75 shares during the period. Asset Planning Inc purchased a new stake in shares of Zoetis in the 4th quarter valued at $58,000. Finally, Quarry LP lifted its stake in Zoetis by 45.9% during the 3rd quarter. Quarry LP now owns 305 shares of the company’s stock worth $60,000 after acquiring an additional 96 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the transaction, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. This represents a 2.02 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is currently owned by insiders.

Zoetis Trading Up 0.1 %

NYSE:ZTS opened at $163.22 on Tuesday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.33. The stock has a market cap of $73.09 billion, a P/E ratio of 29.84, a P/E/G ratio of 2.78 and a beta of 0.94. The stock has a 50-day simple moving average of $166.70 and a 200-day simple moving average of $175.22.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. As a group, analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.23%. Zoetis’s dividend payout ratio is presently 36.56%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on ZTS shares. Morgan Stanley dropped their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Leerink Partners assumed coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. UBS Group started coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective on the stock. Finally, Piper Sandler lifted their target price on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Zoetis currently has an average rating of “Buy” and an average price target of $215.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.